Mechanisms of acquired resistance to tyrosine kinase inhibitors - ScienceDirect
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. | Semantic Scholar
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics | PLOS Computational Biology
Cancers | Free Full-Text | Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Managing resistance in chronic myeloid leukemia. | Semantic Scholar
Response and Resistance to BCR-ABL1-Targeted Therapies
A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia | Science Translational Medicine
Imatinib Pathway, Pharmacokinetics/Pharmacodynamics
Imatinib resistance in chronic myeloid leukaemia caused by Bcr-Abl kinase domain and non-Bcr-Abl mutations: a comparison and review. | Australian Medical Student Journal
Bcr-Abl tyrosine-kinase inhibitor - Wikipedia
Imatinib resistance mechanisms. Imatinib resistance can be attributed... | Download Scientific Diagram
PPT - POSSIBLE MECHANISMS OF IMATINIB RESISTANCE PowerPoint Presentation - ID:2706746
Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators - ScienceDirect
IJMS | Free Full-Text | Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL: Cell
shRNA Loss-of-Function Screen Identifies Alternate Pathway for BCR-ABL - Cellecta
Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours | Oncogene
![PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/800ff3e36d003a19dad5dd24b03c15a74f708084/14-Figure3-1.png "PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar")
PDF] Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). | Semantic Scholar
![PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0a9b23d5cd08b70bab6df94e2948ce56a8452958/6-Figure1-1.png "PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar")
PDF] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia | Semantic Scholar
Imatinib Resistance Mutation Analysis - Kinase Domain Test in Delhi | GDIC
Molecular mechanisms of resistance of leukemia to imatinib mesylate - ScienceDirect
Frontiers | Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy | SpringerLink
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells | PLOS ONE
